Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

6.525 -0.365 (-5.30%)
Streaming Delayed Price Updated: 3:25 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,856,421
Open 6.720
Bid (Size) 6.520 (7)
Ask (Size) 6.530 (9)
Prev. Close 6.890
Today's Range 6.225 - 6.770
52wk Range 6.200 - 12.65
Shares Outstanding 266,555,274
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
From Kaskela Law LLC
Via Business Wire

Performance

YTD
-29.9%
-29.9%
1 Month
-24.4%
-24.4%
3 Month
-31.0%
-31.0%
6 Month
-35.8%
-35.8%
1 Year
-44.5%
-44.5%

More News

Read More
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 19, 2025
Via Benzinga
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts
Via Benzinga
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics
Via Benzinga
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
Via Benzinga
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Via Benzinga
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights
Via Benzinga
Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts
Via Benzinga
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Via Benzinga
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Amicus Therapeutics, Inc. - Common Stock publicly traded?
Yes, Amicus Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Amicus Therapeutics, Inc. - Common Stock trade on?
Amicus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amicus Therapeutics, Inc. - Common Stock?
The ticker symbol for Amicus Therapeutics, Inc. - Common Stock is FOLD on the Nasdaq Stock Market
What is the current price of Amicus Therapeutics, Inc. - Common Stock?
The current price of Amicus Therapeutics, Inc. - Common Stock is 6.525
When was Amicus Therapeutics, Inc. - Common Stock last traded?
The last trade of Amicus Therapeutics, Inc. - Common Stock was at 04/10/25 03:25 PM ET
What is the market capitalization of Amicus Therapeutics, Inc. - Common Stock?
The market capitalization of Amicus Therapeutics, Inc. - Common Stock is 1.74B
How many shares of Amicus Therapeutics, Inc. - Common Stock are outstanding?
Amicus Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.